代谢领域的合作研究与授权协议（2019-2026）

本报告分析了代谢领域的 639 项合作研究和授权协议，清楚地、基于证据地展示了整个市场伙伴关係的设计、谈判和执行方式。

目录

执行摘要

第一章：引言

第二章：代谢领域合约趋势

• 介绍
• 过去几年在代谢领域的合作
• 代谢领域的合作关係：依合约类型划分
• 与代谢相关的合作关係：按产业划分
• 代谢相关协作：依发育阶段
• 代谢领域的合作伙伴关係：依技术类型划分
• 代谢领域的合作：按治疗适应症

第三章 代谢领域合伙企业的财务协议条款

• 介绍
• 已揭露的代谢领域合作关係的财务条款和条件
• 代谢领域合作的主要金额
• 代谢领域合约的预付款
• 代谢领域合约的里程碑付款
• 代谢领域的权利金费率

第四章：代谢领域的主要合约和承包公司

• 介绍
• 代谢领域合作最活跃的公司
• 代谢领域最活跃的承包公司名单
• 代谢领域价值排名前列的合约

第五章：代谢领域的合约记录

• 介绍
• 代谢领域内可提供合约的合作协议。

第六章：代谢领域的合约：依治疗标靶划分

• 介绍
• 合约：透过代谢治疗标靶
• 合约记录
• 合约记录 - 代谢领域合约：按公司分类 (AZ)
• 合约记录 - 代谢领域合约：按技术类型分类
• 合约类型的定义
• 关于 Biopharma Research Ltd.
• Current Partnering
• Current Agreements
• 理想合作伙伴近期报告标题

The definitive benchmark for metabolic dealmaking

Metabolic partnering spans a range of large, chronic disease indications, with deal structures reflecting long-term treatment paradigms, significant commercial potential, and evolving innovation across the space.

This report provides a comprehensive and structured analysis of 639 metabolic collaboration and licensing deals, delivering a clear and evidence-based view of how partnerships are designed, negotiated, and executed across the market.

Establish a clear view of market standards

The report enables a precise understanding of how metabolic deals are structured in practice, allowing you to:

• Benchmark comparable transactions with confidence
• Detailed analysis of upfronts, milestones, and royalty structures across relevant deals
• Define realistic market parameters
• Clear insight into how deal terms vary by stage, asset type, and partner profile
• Support valuation and structuring decisions with evidence
• Ground internal discussions in real transaction data rather than assumptions
• Understand how leading companies approach dealmaking
• Visibility into partner behaviour and recurring deal structures across a high-value and commercially driven therapeutic landscape
• Full visibility into deal structure and execution
• Beyond headline deal data, the report provides access to underlying contract documents, enabling a detailed understanding of how agreements are constructed in practice.

This includes:

• Rights granted and retained
• Development and commercialization responsibilities
• Financial structures and payment triggers
• Key contractual provisions and protections
• This level of transparency is critical to understanding how value, risk, and control are allocated within metabolic partnerships, particularly in areas driven by large patient populations and long-term treatment dynamics.
• Designed for real-world BD and strategy use

The report is widely used to:

• Structure and benchmark live transactions
• Prepare for negotiations with well-defined market context
• Evaluate partnership opportunities and counterparties
• Support internal strategy with robust, defensible data
• What's included
• 639 metabolic collaboration and licensing deals
• Financial terms, including upfronts, milestones, and royalties where disclosed
• Fully searchable deal directory (by company, therapy, and technology)
• Direct access to SEC-filed agreements and source documents
• Analysis of deal trends, key transactions, and active dealmakers
• A trusted, evidence-based reference for metabolic dealmaking
• Combining comprehensive deal coverage with contract-level insight, this report provides a trusted, evidence-based reference for how metabolic partnerships are structured, negotiated, and valued.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in metabolic dealmaking

• 2.1. Introduction
• 2.2. Metabolic partnering over the years
• 2.3. Metabolic partnering by deal type
• 2.4. Metabolic partnering by industry sector
• 2.5. Metabolic partnering by stage of development
• 2.6. Metabolic partnering by technology type
• 2.7. Metabolic partnering by therapeutic indication

Chapter 3 - Financial deal terms for metabolic partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for metabolic partnering
• 3.3. Metabolic partnering headline values
• 3.4. Metabolic deal upfront payments
• 3.5. Metabolic deal milestone payments
• 3.6. Metabolic royalty rates

Chapter 4 - Leading metabolic deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in metabolic partnering
• 4.3. List of most active dealmakers in metabolic
• 4.4. Top metabolic deals by value

Chapter 5 - Metabolic contract document directory

• 5.1. Introduction
• 5.2. Metabolic partnering deals where contract document available

Chapter 6 - Metabolic dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by metabolic therapeutic target
• Deal directory
• Deal directory - Metabolic deals by company A-Z
• Deal directory - Metabolic deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Metabolic partnering since 2019
• Figure 2: Metabolic partnering by deal type since 2019
• Figure 3: Metabolic partnering by industry sector since 2019
• Figure 4: Metabolic partnering by stage of development since 2019
• Figure 5: Metabolic partnering by technology type since 2019
• Figure 6: Metabolic partnering by indication since 2019
• Figure 7: Metabolic deals with a headline value
• Figure 8: Metabolic deals with upfront payment values
• Figure 9: Metabolic deals with milestone payment
• Figure 10: Metabolic deals with royalty rates
• Figure 11: Active metabolic dealmaking activity since 2019
• Figure 12: Top metabolic deals by value since 2019